Article
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2018
Rizvi Hira, Sanchez-Vega Francisco, La Konnor, Chatila Walid, Jonsson Philip, Halpenny Darragh, Plodkowski Andrew, Long Niamh, Sauter Jennifer L, Rekhtman Natasha, Hollmann Travis, Schalper Kurt A, Gainor Justin F, Shen Ronglai, Ni Ai, Arbour Kathryn C, Merghoub Taha, Wolchok Jedd, Snyder Alexandra, Chaft Jamie E, Kris Mark G, Rudin Charles M, Socci Nicholas D, Berger Michael F, Taylor Barry S, Zehir Ahmet, Solit David B, Arcila Maria E, Ladanyi Marc, Riely Gregory J, Schultz Nikolaus, Hellmann Matthew D
Abstract excerpt
Purpose Treatment of advanced non-small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of patients. Clinically available tools to optimize use of ICIs and understand the molecular determinants of response are needed. Targeted next-generation sequencing (NGS) is increasingly routine, but its role in identifying predictors of...
Topics
- B7-H1 Antigen
- Carcinoma, Non-Small-Cell Lung
- High-Throughput Nucleotide Sequencing
- Humans
- Lung Neoplasms
- Mutation